Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

NCT ID: NCT05896228

Last Updated: 2025-03-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-20
• Study Completion Date: 2031-03-01

Brief Summary

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.

Conditions

Refractory Multiple Myeloma; Relapsed Multiple Myeloma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Iber-KDd Combination Therapy

Prior to Iber-KDd combination therapy, participants will receive Acetaminophen, Diphenhydramine and Montelukast therapy per protocol. Participants will receive up to eight (8) 28-day cycles of combination Iberdomide (I), Carfilzomib (K), Daratumumab (D), and Dexamethasone (d) (Iber-KDd) therapy. Participants will receive Iber-KDd combination therapy for approximately 8 months. In the absence of disease progression, participants will continue on to Iber monotherapy. Participants with disease progression will discontinue study therapy but will continue to be followed for up to three (3) years after conclusion of Iber-KDd combination therapy.

Group Type: EXPERIMENTAL

Iberdomide

Intervention Type: DRUG

Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:

• Combination therapy: Cycles 1 to 8: 1 mg per day*, Days 1 to 21 every 28 days.
• Monotherapy: Cycles 9 to 20: 1 mg per day*, Days 1 to 21 every 28 days.

(*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy

Carfilzomib

Intervention Type: DRUG

Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows:

• Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15
• Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15.

Daratumumab

Intervention Type: DRUG

Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows:

• Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22
• Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15
• Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1.

Dexamethasone

Intervention Type: DRUG

Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows:

• Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22
• Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15
• Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15.

Acetaminophen

Intervention Type: DRUG

Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:

• Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22
• Cycles 3 through 6: 650 mg/dose on Days 1 and 15
• Cycles 7 and 8: 650 mg/dose on Day 1.

Diphenhydramine

Intervention Type: DRUG

Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows:

• Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22
• Cycles 3 through 6: 25 mg/dose on Days 1 and 15
• Cycles 7 and 8: 25 mg/dose on Day 1.

Montelukast

Intervention Type: DRUG

Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows:

• Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D).

Iber Monotherapy

After completion of Iber-KDd combination therapy, and In the absence of disease progression, participants will then receive up to twelve (12) 28-day cycles of Iberdomide (Iber) monotherapy. Participants will receive Iber monotherapy for up to 12 months or until disease progression. Participants will be followed for up to three (3) years after conclusion of Iber monotherapy. Total study participation is up to five (5) years.

Group Type: EXPERIMENTAL

Iberdomide

Intervention Type: DRUG

Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:

• Combination therapy: Cycles 1 to 8: 1 mg per day*, Days 1 to 21 every 28 days.
• Monotherapy: Cycles 9 to 20: 1 mg per day*, Days 1 to 21 every 28 days.

(*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy

Interventions

Iberdomide

Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:

• Combination therapy: Cycles 1 to 8: 1 mg per day*, Days 1 to 21 every 28 days.
• Monotherapy: Cycles 9 to 20: 1 mg per day*, Days 1 to 21 every 28 days.

(*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy

Intervention Type: DRUG

Carfilzomib

Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows:

• Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15
• Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15.

Intervention Type: DRUG

Daratumumab

Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows:

• Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22
• Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15
• Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1.

Intervention Type: DRUG

Dexamethasone

Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows:

• Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22
• Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15
• Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15.

Intervention Type: DRUG

Acetaminophen

Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:

• Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22
• Cycles 3 through 6: 650 mg/dose on Days 1 and 15
• Cycles 7 and 8: 650 mg/dose on Day 1.

Intervention Type: DRUG

Diphenhydramine

Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows:

• Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22
• Cycles 3 through 6: 25 mg/dose on Days 1 and 15
• Cycles 7 and 8: 25 mg/dose on Day 1.

Intervention Type: DRUG

Montelukast

Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows:

• Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with histologically confirmed MM with progressive disease according to the IMWG criteria 47 during or within 60 days of their last regimen who have received 1-3 lines of prior therapy (inclusive of a lenalidomide-containing regimen) and have measurable disease within 4 weeks of enrollment based on one of the following:

• Serum monoclonal protein ≥ 1.0 g/dL
• Urine monoclonal protein ≥ 200 mg/24 hour
• Involved serum immunoglobulin free light chains (FLC) ≥ 10 mg/dL AND abnormal kappa/lambda ratio.

Note: Because the primary endpoint is MRD-negativity rate, per the discretion of the Principal Investigator (PI), patients without measurable disease (e.g., M-spike < 1.0 g/dL) may also be enrolled in line with the IMWG MM response criteria 47.

2. Prior treatment with cluster of differentiation 38 (CD38) -directed therapy is permitted only if all the following are fulfilled:

• Best response achieved during CD38-directed therapy was ≥ PR.
• Patient did not progress while receiving CD38-directed therapy or within 60 days of last dose of therapy.
• Patient did not discontinue CD38-directed therapy due to a related AE.

3. Prior treatment with carfilzomib is permitted only if all the following are fulfilled:

• Best response achieved during carfilzomib-based therapy was ≥ PR.
• Patient did not progress while receiving carfilzomib-based therapy or within 60 days of last dose of therapy.
• Patient did not discontinue carfilzomib due to a related AE.

4. Creatinine Clearance (CrCl) ≥60 ml/min measured within 4 weeks of enrollment. CrCl can be measured or estimated using Cockcroft-Gault method, Modification of Diet in Renal Disease (MDRD), or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae.

5. Age ≥ 18 years at the time of signing the informed consent documentation. Age limit of 75 years.

6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 within 4 weeks of enrollment (Appendix A).

7. Absolute neutrophil count (ANC) ≥ 1.0 K cells/µL, hemoglobin ≥ 8 g/dL, and platelet count ≥ 50 K platelets/µL measured within 4 weeks of enrollment unless cytopenias are deemed to be due to disease at the discretion of the clinical Investigator. Transfusions and administration of growth factors are permissible.

8. Adequate hepatic function with bilirubin < 1.5 x the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN measured within 4 weeks of enrollment.

9. All study participants must be able to tolerate one of the following thromboprophylactic strategies: oral factor Xa inhibitors or low molecular weight heparin or alternative anti-coagulant.

10. Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test within 10-14 days and again within 24 hours prior to prescribing of iberdomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, at the same time at least 28 days before she starts taking iberdomide without interruption. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.

• A FCBP is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Females who do not meet the above definition of FCBP should be classified as females not of childbearing potential (FNCBP).

3. Patients with plasma cell leukemia.

4. Patients with Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes syndrome (POEMS syndrome).

5. Patients with amyloidosis.

6. Patients with known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal within 4 weeks of enrollment.

Note: FEV1 testing is required for patients suspected of having COPD, and patients must be excluded if FEV1 < 50% of predicted normal at any time during the study.

7. Pregnant or lactating females. Because there is a potential risk for AEs in nursing infants secondary to treatment of the mother with carfilzomib in combination with iberdomide, pregnant or lactating females are excluded from study participation. These potential risks may also apply to other agents used in this study.

8. Uncontrolled hypertension (ie, systolic blood pressure [BP] > 160 mmHg, diastolic BP > 100 mmHg) or diabetes

9. Patients with active hepatitis B or C infection.

10. Patient is:

• Seropositive for human immunodeficiency virus (HIV) (Section 10.3.5.1) within 4 weeks of enrollment.
• Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]) within 4 weeks of enrollment. Patients with resolved infection (i.e., patients who are HBsAg negative but positive for antibodies to hepatitis B core antigen (anti-HBc) and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (RT-PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Patients with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR.
• Seropositive for hepatitis C (except in the setting of a sustained virologic response (SVR), defined as aviremia at least 12 weeks after completion of antiviral therapy).

For more information regarding the timing and frequency of hepatitis testing, refer to Section 10.3.5.1.

11. Significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, symptomatic ischemia, current uncontrolled arrhythmias, screening electrocardiogram (ECG) with corrected QT interval (QTc) of > 470 msec within 4 weeks of enrollment, pericardial disease, or myocardial infarction within 4 months prior to enrollment, and left ventricular ejection fraction (EF) < 40% as assessed by transthoracic echocardiogram (ECHO) within 4 weeks of enrollment. Current unstable angina as determined by history and physical exam, hypertrophic cardiomyopathy or restrictive cardiomyopathy

12. Pulmonary hypertension

13. Has refractory gastrointestinal (GI) disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption of oral agents

14. Uncontrolled intercurrent illness including but not limited to active infection or psychiatric illness/social situations that would compromise compliance with study requirements

15. Significant neuropathy ≥ Grade 3 with pain at baseline

16. Contraindication to any concomitant medication, including antivirals or anticoagulation

17. Major surgery within 3 weeks prior to first dose

18. Prior treatment with iberdomide

19. For female patients: Patient plans to become pregnant or donate eggs during the Treatment Period and/or required period for contraception use post-last dose of study treatment.

20. For male patients: Patient plans to father a child or donate sperm during the Treatment Period and/or required period for contraception use post-last dose of study treatment.

21. Patients with limited decision-making capacity.

Exclusion Criteria

1. Patients receiving concurrent systemic treatment for MM with the following exceptions:

• Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted.
• Patients may receive kyphoplasty/vertebroplasty for symptomatic vertebral compression fractures.
• Bone targeting agents are permitted.
• Concurrent or prior treatment with corticosteroids for indications other than MM is permitted.
• Focal radiation therapy within 14 days prior to randomization with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma.
• Prior MM treatments must be concluded with a washout period of 2 weeks from last dose.

2. Patients who are refractory to an anti-CD38-directed regimen:

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

Benjamin T Diamond, MD

OTHER

Sponsor Role: lead

Responsible Party

Benjamin T Diamond, MD

Assistant Professor of Clinical

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Carl O Landgren, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Miami

Benjamin Diamond, MD

Role: PRINCIPAL_INVESTIGATOR

University of Miami

Locations

University of Miami

Miami, Florida, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Michelle D Armogan

Role: CONTACT

mda182@med.miami.edu

305-243-7479

Facility Contacts

Michelle D Armogan

Role: primary

mda182@med.miami.edu

305-243-7479

Other Identifiers

20230227

Identifier Type: -

Identifier Source: org_study_id